Management Team

Paul A. Grayson
President and Chief Executive Officer

Mr. Paul Grayson previously served as CEO of Fate Therapeutics (NASDAQ: FATE). Before this, he was managing director of Sanderling Ventures. Prior to Sanderling, Mr. Grayson served as the founding Chairman and CEO of Senomyx Inc. (NASDAQ: SNMX).

Anke Kretz-Rommel, PhD
Chief Technology Officer

Dr. Anke Kretz-Rommel has more than 20 years of experience in discovering and developing antibodies for the treatment of cancer and autoimmune and inflammatory diseases. Prior to Bird Rock Bio, she led multiple discovery and development efforts as head of the Cellular Immunology group at Alexion Antibody Technologies and was a key investigator on a first-in-class drug currently in clinical trials for chronic lymphocytic leukemia, leading the program from discovery through preclinical modeling and pre-IND preparation. Dr. Kretz-Rommel received her Ph.D. in toxicology from the ETH Zurich, Switzerland.

Alan Glicklich, MD
Chief Medical Officer

Dr. Alan Glicklich previously served as vice president of clinical development of Arena Pharmaceuticals. Prior to Arena, he was the vice president of clinical affairs of Savient Pharmaceuticals and before that the vice president of clinical development of Veloxis Pharmaceuticals. Dr. Glicklich has also served in senior clinical positions at Mitsubishi-Tanabe Development America, Bristol Myers Squibb, Sanofi-Aventis and Regeneron. He holds a medical degree from the University of Wisconsin, an MBA from Emory University and BA in Biology from the University of Chicago.